Accumulating evidence indicates that PAK1 is overexpression in diverse malignant tumours such as non‐small cell lung cancer, breast cancer, hepatocellular carcinoma and pancreatic cancer, and high expression of PAK1 is positively associated with high risk of tumour recurrence and metastasis, and poor survival.37, 38, 39, 40. Here, PAK1 is linked to hepatocellular carcinoma.